Cargando…
Transcript profiling of different types of multiple sclerosis lesions yields FGF1 as a promoter of remyelination
Chronic demyelination is a pathological hallmark of multiple sclerosis (MS). Only a minority of MS lesions remyelinates completely. Enhancing remyelination is, therefore, a major aim of future MS therapies. Here we took a novel approach to identify factors that may inhibit or support endogenous remy...
Autores principales: | , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4359505/ https://www.ncbi.nlm.nih.gov/pubmed/25589163 http://dx.doi.org/10.1186/s40478-014-0168-9 |
_version_ | 1782361419834982400 |
---|---|
author | Mohan, Hema Friese, Anita Albrecht, Stefanie Krumbholz, Markus Elliott, Christina L Arthur, Ariel Menon, Ramesh Farina, Cinthia Junker, Andreas Stadelmann, Christine Barnett, Susan C Huitinga, Inge Wekerle, Hartmut Hohlfeld, Reinhard Lassmann, Hans Kuhlmann, Tanja Linington, Chris Meinl, Edgar |
author_facet | Mohan, Hema Friese, Anita Albrecht, Stefanie Krumbholz, Markus Elliott, Christina L Arthur, Ariel Menon, Ramesh Farina, Cinthia Junker, Andreas Stadelmann, Christine Barnett, Susan C Huitinga, Inge Wekerle, Hartmut Hohlfeld, Reinhard Lassmann, Hans Kuhlmann, Tanja Linington, Chris Meinl, Edgar |
author_sort | Mohan, Hema |
collection | PubMed |
description | Chronic demyelination is a pathological hallmark of multiple sclerosis (MS). Only a minority of MS lesions remyelinates completely. Enhancing remyelination is, therefore, a major aim of future MS therapies. Here we took a novel approach to identify factors that may inhibit or support endogenous remyelination in MS. We dissected remyelinated, demyelinated active, and demyelinated inactive white matter MS lesions, and compared transcript levels of myelination and inflammation-related genes using quantitative PCR on customized TaqMan Low Density Arrays. In remyelinated lesions, fibroblast growth factor (FGF) 1 was the most abundant of all analyzed myelination-regulating factors, showed a trend towards higher expression as compared to demyelinated lesions and was significantly higher than in control white matter. Two MS tissue blocks comprised lesions with adjacent de- and remyelinated areas and FGF1 expression was higher in the remyelinated rim compared to the demyelinated lesion core. In functional experiments, FGF1 accelerated developmental myelination in dissociated mixed cultures and promoted remyelination in slice cultures, whereas it decelerated differentiation of purified primary oligodendrocytes, suggesting that promotion of remyelination by FGF1 is based on an indirect mechanism. The analysis of human astrocyte responses to FGF1 by genome wide expression profiling showed that FGF1 induced the expression of the chemokine CXCL8 and leukemia inhibitory factor, two factors implicated in recruitment of oligodendrocytes and promotion of remyelination. Together, this study presents a transcript profiling of remyelinated MS lesions and identified FGF1 as a promoter of remyelination. Modulation of FGF family members might improve myelin repair in MS. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s40478-014-0168-9) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-4359505 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-43595052015-03-15 Transcript profiling of different types of multiple sclerosis lesions yields FGF1 as a promoter of remyelination Mohan, Hema Friese, Anita Albrecht, Stefanie Krumbholz, Markus Elliott, Christina L Arthur, Ariel Menon, Ramesh Farina, Cinthia Junker, Andreas Stadelmann, Christine Barnett, Susan C Huitinga, Inge Wekerle, Hartmut Hohlfeld, Reinhard Lassmann, Hans Kuhlmann, Tanja Linington, Chris Meinl, Edgar Acta Neuropathol Commun Research Article Chronic demyelination is a pathological hallmark of multiple sclerosis (MS). Only a minority of MS lesions remyelinates completely. Enhancing remyelination is, therefore, a major aim of future MS therapies. Here we took a novel approach to identify factors that may inhibit or support endogenous remyelination in MS. We dissected remyelinated, demyelinated active, and demyelinated inactive white matter MS lesions, and compared transcript levels of myelination and inflammation-related genes using quantitative PCR on customized TaqMan Low Density Arrays. In remyelinated lesions, fibroblast growth factor (FGF) 1 was the most abundant of all analyzed myelination-regulating factors, showed a trend towards higher expression as compared to demyelinated lesions and was significantly higher than in control white matter. Two MS tissue blocks comprised lesions with adjacent de- and remyelinated areas and FGF1 expression was higher in the remyelinated rim compared to the demyelinated lesion core. In functional experiments, FGF1 accelerated developmental myelination in dissociated mixed cultures and promoted remyelination in slice cultures, whereas it decelerated differentiation of purified primary oligodendrocytes, suggesting that promotion of remyelination by FGF1 is based on an indirect mechanism. The analysis of human astrocyte responses to FGF1 by genome wide expression profiling showed that FGF1 induced the expression of the chemokine CXCL8 and leukemia inhibitory factor, two factors implicated in recruitment of oligodendrocytes and promotion of remyelination. Together, this study presents a transcript profiling of remyelinated MS lesions and identified FGF1 as a promoter of remyelination. Modulation of FGF family members might improve myelin repair in MS. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s40478-014-0168-9) contains supplementary material, which is available to authorized users. BioMed Central 2014-12-11 /pmc/articles/PMC4359505/ /pubmed/25589163 http://dx.doi.org/10.1186/s40478-014-0168-9 Text en © Mohan et al.; licensee BioMed Central. 2014 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Article Mohan, Hema Friese, Anita Albrecht, Stefanie Krumbholz, Markus Elliott, Christina L Arthur, Ariel Menon, Ramesh Farina, Cinthia Junker, Andreas Stadelmann, Christine Barnett, Susan C Huitinga, Inge Wekerle, Hartmut Hohlfeld, Reinhard Lassmann, Hans Kuhlmann, Tanja Linington, Chris Meinl, Edgar Transcript profiling of different types of multiple sclerosis lesions yields FGF1 as a promoter of remyelination |
title | Transcript profiling of different types of multiple sclerosis lesions yields FGF1 as a promoter of remyelination |
title_full | Transcript profiling of different types of multiple sclerosis lesions yields FGF1 as a promoter of remyelination |
title_fullStr | Transcript profiling of different types of multiple sclerosis lesions yields FGF1 as a promoter of remyelination |
title_full_unstemmed | Transcript profiling of different types of multiple sclerosis lesions yields FGF1 as a promoter of remyelination |
title_short | Transcript profiling of different types of multiple sclerosis lesions yields FGF1 as a promoter of remyelination |
title_sort | transcript profiling of different types of multiple sclerosis lesions yields fgf1 as a promoter of remyelination |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4359505/ https://www.ncbi.nlm.nih.gov/pubmed/25589163 http://dx.doi.org/10.1186/s40478-014-0168-9 |
work_keys_str_mv | AT mohanhema transcriptprofilingofdifferenttypesofmultiplesclerosislesionsyieldsfgf1asapromoterofremyelination AT frieseanita transcriptprofilingofdifferenttypesofmultiplesclerosislesionsyieldsfgf1asapromoterofremyelination AT albrechtstefanie transcriptprofilingofdifferenttypesofmultiplesclerosislesionsyieldsfgf1asapromoterofremyelination AT krumbholzmarkus transcriptprofilingofdifferenttypesofmultiplesclerosislesionsyieldsfgf1asapromoterofremyelination AT elliottchristinal transcriptprofilingofdifferenttypesofmultiplesclerosislesionsyieldsfgf1asapromoterofremyelination AT arthurariel transcriptprofilingofdifferenttypesofmultiplesclerosislesionsyieldsfgf1asapromoterofremyelination AT menonramesh transcriptprofilingofdifferenttypesofmultiplesclerosislesionsyieldsfgf1asapromoterofremyelination AT farinacinthia transcriptprofilingofdifferenttypesofmultiplesclerosislesionsyieldsfgf1asapromoterofremyelination AT junkerandreas transcriptprofilingofdifferenttypesofmultiplesclerosislesionsyieldsfgf1asapromoterofremyelination AT stadelmannchristine transcriptprofilingofdifferenttypesofmultiplesclerosislesionsyieldsfgf1asapromoterofremyelination AT barnettsusanc transcriptprofilingofdifferenttypesofmultiplesclerosislesionsyieldsfgf1asapromoterofremyelination AT huitingainge transcriptprofilingofdifferenttypesofmultiplesclerosislesionsyieldsfgf1asapromoterofremyelination AT wekerlehartmut transcriptprofilingofdifferenttypesofmultiplesclerosislesionsyieldsfgf1asapromoterofremyelination AT hohlfeldreinhard transcriptprofilingofdifferenttypesofmultiplesclerosislesionsyieldsfgf1asapromoterofremyelination AT lassmannhans transcriptprofilingofdifferenttypesofmultiplesclerosislesionsyieldsfgf1asapromoterofremyelination AT kuhlmanntanja transcriptprofilingofdifferenttypesofmultiplesclerosislesionsyieldsfgf1asapromoterofremyelination AT liningtonchris transcriptprofilingofdifferenttypesofmultiplesclerosislesionsyieldsfgf1asapromoterofremyelination AT meinledgar transcriptprofilingofdifferenttypesofmultiplesclerosislesionsyieldsfgf1asapromoterofremyelination |